Canada Must Learn ‘Difficult Lessons’ From COVID-19
CGPA’s Keon Urges Strengthening Domestic Industry Amid Global Supply Chain
Canadian policymakers must learn “difficult lessons” from the coronavirus pandemic and support measures to bolster domestic production and secure the country’s position as part of the global supply chain, according to CGPA president Jim Keon.
You may also be interested in...
In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.
In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.